Moldova Pharmaceuticals & Healthcare Q4 2018
Moldova's operating environment remains unattractive to pharmaceutical companies. The small market size with limitedgrowth potential for high value medicines will discourage drugmakers from investing in the country. Moreover, high levels ofindustry- and country-specific risks, such as an uncertain pricing regime and high political risk, will augment the challenges faced bycompanies marketing their products in Moldova.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook